MXPA05006169A - Compositions and methods of delivery of pharmacological agents. - Google Patents
Compositions and methods of delivery of pharmacological agents.Info
- Publication number
- MXPA05006169A MXPA05006169A MXPA05006169A MXPA05006169A MXPA05006169A MX PA05006169 A MXPA05006169 A MX PA05006169A MX PA05006169 A MXPA05006169 A MX PA05006169A MX PA05006169 A MXPA05006169 A MX PA05006169A MX PA05006169 A MXPA05006169 A MX PA05006169A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- pharmaceutical composition
- delivery
- compositions
- pharmacological agents
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 2
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 abstract 1
- 229960000958 deferoxamine Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- -1 for example Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/701—Integrated with dissimilar structures on a common substrate
- Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
- Y10S977/705—Protein or peptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
- Y10S977/779—Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/911—Cancer cell destruction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43231702P | 2002-12-09 | 2002-12-09 | |
US22551903A | 2003-12-03 | 2003-12-03 | |
US22554903A | 2003-12-04 | 2003-12-04 | |
US22558503A | 2003-12-05 | 2003-12-05 | |
PCT/US2003/038941 WO2004052401A2 (en) | 2002-12-09 | 2003-12-09 | Compositions and methods of delivery of pharmacological agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05006169A true MXPA05006169A (en) | 2006-03-30 |
Family
ID=32512525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05006169A MXPA05006169A (en) | 2002-12-09 | 2003-12-09 | Compositions and methods of delivery of pharmacological agents. |
Country Status (6)
Country | Link |
---|---|
KR (8) | KR20190034694A (en) |
BR (1) | BR0317134A (en) |
MX (1) | MXPA05006169A (en) |
NZ (1) | NZ541142A (en) |
PT (1) | PT1585548T (en) |
WO (1) | WO2004052401A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
CN102532120A (en) | 2002-08-23 | 2012-07-04 | 索隆-基特林癌症研究协会 | Synthesis of EPOTHILONE, intermediates thereto, analogues and uses thereof |
EP3470084A1 (en) | 2002-12-09 | 2019-04-17 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
US8476010B2 (en) | 2003-07-10 | 2013-07-02 | App Pharmaceuticals Llc | Propofol formulations with non-reactive container closures |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
PT1853250E (en) * | 2005-02-18 | 2012-02-03 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
CN101184481A (en) * | 2005-02-18 | 2008-05-21 | 阿布拉西斯生物科学公司 | Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury |
CN100358513C (en) * | 2005-04-07 | 2008-01-02 | 常州市第四制药厂有限公司 | Disoprofol injection preparation process |
CN104189905A (en) | 2005-08-31 | 2014-12-10 | 阿布拉科斯生物科学有限公司 | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
WO2007027941A2 (en) * | 2005-08-31 | 2007-03-08 | Abraxis Bioscience, Llc. | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
US20100166872A1 (en) * | 2005-10-21 | 2010-07-01 | Amarjit Singh | Novel improved compositions for cancer therapy |
JP5385785B2 (en) * | 2006-08-23 | 2014-01-08 | ブルー メディカル デバイシーズ ベーフェー | Medical stent with a combination of melatonin and paclitaxel |
MX2009002054A (en) * | 2006-08-31 | 2009-05-01 | Abraxis Bioscience Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases. |
JP5933893B2 (en) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス, エルエルシー | Breast cancer therapy using nanoparticles containing taxanes based on hormone receptor status |
UA118645C2 (en) | 2007-03-07 | 2019-02-25 | Абраксіс Байосайєнс, Елелсі. | METHOD OF COMBINED CANCER THERAPY OF NANOPARTICLES CONTAINING RAPAMYCINE AND ALBUMIN |
US7943591B2 (en) | 2007-05-11 | 2011-05-17 | Adynxx, Inc. | Gene expression and pain |
CA2689914C (en) | 2007-06-01 | 2016-08-16 | Abraxis Bioscience, Llc | Use of protein-bound taxane nanoparticles in the treatment of recurrent gynecological cancers |
AU2009216757A1 (en) * | 2008-02-19 | 2009-08-27 | Novartis Ag | Combination of an iron chelator and an immunosuppressant and use thereof |
RU2528855C2 (en) | 2008-06-24 | 2014-09-20 | Цсл Беринг Гмбх | Modified von willebrand factor with prolonged half-cycle in vivo, using it and methods for preparing |
JP5781500B2 (en) | 2009-04-15 | 2015-09-24 | アブラクシス バイオサイエンス, エルエルシー | Nanoparticle compositions and methods without prions |
ES2580135T3 (en) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Methods of treatment of hepatocellular carcinoma |
NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
CN107158389A (en) | 2010-03-29 | 2017-09-15 | 阿布拉科斯生物科学有限公司 | Strengthen the method for medicine delivery and therapeutic agent validity |
AU2011261685B2 (en) | 2010-06-04 | 2016-02-11 | Abraxis Bioscience, Llc | Methods of treatment of pancreatic cancer |
JP6124348B2 (en) * | 2011-09-27 | 2017-05-10 | 公立大学法人横浜市立大学 | Tissue and organ production methods |
RU2019134053A (en) | 2011-12-14 | 2019-12-11 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | APPLICATION OF POLYMERIC EXCIPIENTS FOR LYOFILIZATION OR FREEZING OF PARTICLES |
CA2872901A1 (en) * | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
CN105228612A (en) | 2013-03-12 | 2016-01-06 | 阿布拉科斯生物科学有限公司 | The method for the treatment of pulmonary carcinoma |
RU2015143490A (en) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | METHODS FOR TREATING BLADDER CANCER |
EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
US20170000899A1 (en) * | 2013-11-26 | 2017-01-05 | The Brigham And Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
ES2750689T3 (en) | 2014-08-15 | 2020-03-26 | Adynxx Inc | Oligonucleotide lures for pain management |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
KR20230165356A (en) | 2015-06-29 | 2023-12-05 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of treating epithelioid cell tumors |
EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
CN115003284A (en) | 2019-10-28 | 2022-09-02 | 阿布拉科斯生物科学有限公司 | Pharmaceutical composition of albumin and rapamycin |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56125317A (en) * | 1980-03-08 | 1981-10-01 | Nippon Mejifuijitsukusu Kk | Stable radioactive diagnosticum with radioactive metallic mark |
JPS59199636A (en) * | 1983-04-26 | 1984-11-12 | Nippon Mejifuijitsukusu Kk | Radioactive diagnostic agent and production thereof |
EP0227593A1 (en) * | 1985-11-25 | 1987-07-01 | The Hospital For Sick Children | Use of chelating agents |
JPH06502177A (en) * | 1990-10-16 | 1994-03-10 | バイオメディカル・フロンティアーズ・インコーポレイテッド | Magnetic resonance imaging polymer-deferoxamine-ferric adduct |
DE4139001A1 (en) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | PROCESS FOR INJECTION OF NUCLEAR ACIDS IN CELLS |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
CN1195995A (en) * | 1995-09-21 | 1998-10-14 | 安达里斯有限公司 | Transcytosis vehicles and enhancers for drug delivery |
DE19636889A1 (en) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastic transferrin and albumin conjugates of cytostatic compounds from the group of the anthracyclines, alkylating agents, antimetabolites and cisplatin analogues and medicaments containing them |
US5990153A (en) * | 1997-05-05 | 1999-11-23 | Wood; John G. | Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury |
FR2775900A1 (en) * | 1998-03-10 | 1999-09-17 | Charles Dumontet | Use of deferoxamine to reduce toxicity of anthracyclines |
WO2000023117A1 (en) * | 1998-10-16 | 2000-04-27 | The General Hospital Corporation | Photosensitizer conjugates for targeting intracellular pathogens |
AU2003251906B2 (en) * | 2002-07-12 | 2008-12-04 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
-
2003
- 2003-12-09 PT PT03799876T patent/PT1585548T/en unknown
- 2003-12-09 KR KR1020197008420A patent/KR20190034694A/en not_active IP Right Cessation
- 2003-12-09 KR KR1020127011409A patent/KR20120068035A/en not_active Application Discontinuation
- 2003-12-09 KR KR1020147033814A patent/KR20140148502A/en not_active Application Discontinuation
- 2003-12-09 KR KR1020057010482A patent/KR20050095826A/en not_active Application Discontinuation
- 2003-12-09 KR KR1020187024645A patent/KR20180098702A/en not_active Application Discontinuation
- 2003-12-09 BR BR0317134-5A patent/BR0317134A/en not_active Application Discontinuation
- 2003-12-09 KR KR1020147003448A patent/KR20140027554A/en not_active Application Discontinuation
- 2003-12-09 MX MXPA05006169A patent/MXPA05006169A/en unknown
- 2003-12-09 KR KR1020157025001A patent/KR20150108943A/en not_active Application Discontinuation
- 2003-12-09 WO PCT/US2003/038941 patent/WO2004052401A2/en active Application Filing
- 2003-12-09 NZ NZ541142A patent/NZ541142A/en not_active IP Right Cessation
- 2003-12-09 KR KR1020117011747A patent/KR20110079741A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20150108943A (en) | 2015-09-30 |
KR20190034694A (en) | 2019-04-02 |
BR0317134A (en) | 2005-11-22 |
KR20050095826A (en) | 2005-10-04 |
WO2004052401A3 (en) | 2005-02-17 |
PT1585548T (en) | 2018-10-17 |
KR20110079741A (en) | 2011-07-07 |
NZ541142A (en) | 2008-07-31 |
KR20140148502A (en) | 2014-12-31 |
KR20180098702A (en) | 2018-09-04 |
KR20120068035A (en) | 2012-06-26 |
KR20140027554A (en) | 2014-03-06 |
WO2004052401A2 (en) | 2004-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05006169A (en) | Compositions and methods of delivery of pharmacological agents. | |
TR200502189T1 (en) | Compositions and methods for the transfer of pharmacologically active substances. | |
EP0783299A4 (en) | Compounds and compositions for delivering active agents | |
HK1036970A1 (en) | Compounds and compositions for delivering active agents. | |
EP1015008A4 (en) | Compounds and compositions for delivering active agents | |
MXPA01008611A (en) | Compounds and compositions for delivering active agents. | |
AU7315301A (en) | Compounds and compositions for delivering active agents | |
AU2274201A (en) | Compounds and compositions for delivering active agents | |
IL195055A (en) | Phenoxy carboxylic acid compounds and compositions for delivering active agents | |
IL140930A0 (en) | Compounds and compositions for delivering active agents | |
WO2001041779A3 (en) | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment | |
WO2006082588A3 (en) | Method and device for ophthalmic administration of active pharmaceutical ingredients | |
NO20024586D0 (en) | Method and preparations to prevent hormone-induced side effects | |
TNSN08511A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
UA85993C2 (en) | Conjugate of a bacterial superantigen and antibody moiety, pharmaceutical composition containing thereof and method for treatment of cancer in mammals | |
MXPA04004567A (en) | Phenoxy amine compounds and compositions for delivering active agents. | |
MXPA03007857A (en) | Compounds and compositions for delivering active agents. | |
AU3492100A (en) | Oxadiazole compounds and compositions for delivering active agents | |
MY141012A (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
WO2002015892A3 (en) | Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors | |
HK1045458B (en) | Ophthalmic histamine compositions and uses thereof | |
AR034749A1 (en) | FORMULATIONS OF HUMAN BETA INTERFERON | |
AU2001267561A1 (en) | Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents | |
WO2001070184A3 (en) | A composition containing monoterpenes for topical oral administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |